Free
Correspondence  |   July 2008
Efficacy of Intravenous Iron Sucrose Administration for Correcting Preoperative Anemia in Patients Scheduled for Major Orthopedic Surgery
Author Affiliations & Notes
  • Oliver M. Theusinger, M.D.
    *
  • *University Hospital and University of Zurich, Zurich, Switzerland.
Article Information
Correspondence
Correspondence   |   July 2008
Efficacy of Intravenous Iron Sucrose Administration for Correcting Preoperative Anemia in Patients Scheduled for Major Orthopedic Surgery
Anesthesiology 7 2008, Vol.109, 152. doi:10.1097/ALN.0b013e31817b89fe
Anesthesiology 7 2008, Vol.109, 152. doi:10.1097/ALN.0b013e31817b89fe
In Reply:—
We thank Dr. Cuenca et al.  for their comments on our article about the efficacy of intravenous iron sucrose in the treatment of preoperative anemia in patients undergoing major orthopedic surgery,1 and are glad to answer their comments.
We used the World Health Organization definition for anemia as inclusion criteria for our study and reviewed the literature concerning iron deficiency anemia. Interestingly, there is not one universally applicable definition for iron deficiency anemia. Recent papers by Thomas et al.  2–4 indicate that the traditional definition for iron deficiency anemia with mean corpuscular volume < 80 fl or a ferritin level < 15–30 μg/l or transferrin saturation < 15% does not take into account the effect of a possible inflammatory state. Therefore, we measured C-reactive protein as well as leukocyte count for every patient at the moment of inclusion. Leukocyte counts ranged from 4,300 to 9,500/μl (reference values being 4,000–10,000/μl in our laboratory) and C-reactive protein ranged from 0 to 12 mg/l (reference, < 7 mg/l). By measuring the soluble transferrin receptor and calculating the ferritin index (soluble transferrin receptor/log ferritin ratio), and using different cutoff values depending on the measured C-reactive protein, we were able to select iron deficiency anemia.
The theoretical total iron deficit for a target hemoglobin of 15 g/dl was calculated for every patient. Total iron deficit was 1,088 ± 239 mg, indicating that the administered dose of 900 mg was indeed slightly less than theoretically needed. Therefore, higher doses may be used in future studies. The perioperative blood loss was not considered in the calculation of the total iron dose, because only the preoperative hemoglobin increase was assessed.
We compared the transfusion outcome of our group of patients with the study of Cuenca et al.  5 and found astonishing similarities in both groups treated with intravenous iron. Comparing our results with a combined erythropoietin and intravenous iron treatment6 or a treatment with oral iron7 appears inadequate.8 
The question on repeated low dose intravenous iron was assessed in patients on hemodialysis.9 Schiesser et al.  9 showed that it is possible to maintain the iron status and the hemoglobin level with low dose intravenous iron. However, such a regimen did not allow improving the hemoglobin level. Nevertheless, in orthopedic surgery a direct comparison between repeated low dose versus  high dose intravenous iron regimen may be the subject of a future study.
In conclusion, intravenous iron should be considered for the relative rapid correction of iron deficiency anemia. However, the real benefit of such a regimen in the context of (orthopedic) surgery needs to be proven in a future prospective, randomized, placebo-controlled trial.
*University Hospital and University of Zurich, Zurich, Switzerland.
References
Theusinger OM, Leyvraz PF, Schanz U, Seifert B, Spahn DR: Treatment of iron deficiency anemia in orthopedic surgery with intravenous iron: Efficacy and limits: A prospective study. Anesthesiology 2007; 107:923–7Theusinger, OM Leyvraz, PF Schanz, U Seifert, B Spahn, DR
Thomas C, Kirschbaum A, Boehm D, Thomas L: The diagnostic plot: A concept for identifying different states of iron deficiency and monitoring the response to epoetin therapy. Med Oncol 2006; 23:23–36Thomas, C Kirschbaum, A Boehm, D Thomas, L
Thomas L, Thomas C: Anemia in iron deficiency and disorders of iron metabolism [in German]. Dtsch Med Wochenschr 2002; 127:1591–4Thomas, L Thomas, C
Thomas C, Thomas L: Anemia of chronic disease: Pathophysiology and laboratory diagnosis. Lab Hematol 2005; 11:14–23Thomas, C Thomas, L
Cuenca J, García-Erce JA, Munoz M, Izuel M, Martinez AA, Herrera A: Patients with pertrochanteric hip fracture may benefit from preoperative intravenous iron therapy: A pilot study. Transfusion 2004; 44:1447–52Cuenca, J García-Erce, JA Munoz, M Izuel, M Martinez, AA Herrera, A
García-Erce JA, Cuenca J, Munoz M, Izuel M, Martinez AA, Herrera A, Solano VM, Martinez F: Perioperative stimulation of erythropoiesis with intravenous iron and erythropoietin reduces transfusion requirements in patients with hip fracture. A prospective observational study. Vox Sang 2005; 88:235–43García-Erce, JA Cuenca, J Munoz, M Izuel, M Martinez, AA Herrera, A Solano, VM Martinez, F
Cuenca J, García-Erce JA, Martinez F, Cardona R, Perez-Serrano L, Munoz M: Preoperative haematinics and transfusion protocol reduce the need for transfusion after total knee replacement. Int J Surg 2007; 5:89–94Cuenca, J García-Erce, JA Martinez, F Cardona, R Perez-Serrano, L Munoz, M
Van Wyck DB, Roppolo M, Martinez CO, Mazey RM, McMurray S: A randomized, controlled trial comparing IV iron sucrose to oral iron in anemic patients with nondialysis-dependent CKD. Kidney Int 2005; 68:2846–56Van Wyck, DB Roppolo, M Martinez, CO Mazey, RM McMurray, S
Schiesser D, Binet I, Tsinalis D, Dickenmann M, Keusch G, Schmidli M, Ambuhl PM, Luthi L, Wuthrich RP: Weekly low-dose treatment with intravenous iron sucrose maintains iron status and decreases epoetin requirement in iron-replete haemodialysis patients. Nephrol Dial Transplant 2006; 21:2841–5Schiesser, D Binet, I Tsinalis, D Dickenmann, M Keusch, G Schmidli, M Ambuhl, PM Luthi, L Wuthrich, RP